SUN-LB280: Double Blind Multicenter Phase III Gortec Trial Evaluating the Efficacy of Oral Immune Modulating Formulae Therapy During Adjuvant Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). (September 2016)